Trials / Completed
CompletedNCT05981963
A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants
A Phase 1, Single-center, Open-label Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of Orally Administered 60 mg BMS-986196, Including Radioactively Labeled [14C]-BMS-986196, in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the excretion pathway of orally administered \[14C\]-BMS-986196 and to assess the safety and tolerability of orally administered BMS-986196.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-BMS-986196 | Specified dose on specified days |
Timeline
- Start date
- 2023-08-17
- Primary completion
- 2023-10-22
- Completion
- 2023-10-22
- First posted
- 2023-08-08
- Last updated
- 2023-11-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05981963. Inclusion in this directory is not an endorsement.